Regulation of mineralocorticoid receptor expression during neuronal differentiation of murine embryonic stem cells.

Mathilde Munier, Geri Meduri, Say Viengchareun, Phillipe Leclerc, Damien Le Menuet, Marc Lombès

▶ **To cite this version:**

Mathilde Munier, Geri Meduri, Say Viengchareun, Phillipe Leclerc, Damien Le Menuet, et al.. Regulation of mineralocorticoid receptor expression during neuronal differentiation of murine embryonic stem cells.. Endocrinology, 2010, 151 (5), pp.2244-54. 10.1210/en.2009-0753 . inserm-00450814

1 # Regulation of Mineralocorticoid Receptor Expression during Neuronal

2 # Differentiation of Murine Embryonic Stem Cells

3

4 **Abbreviated title:** MR in ES-derived Neurons

5

6 **Précis:**

7 Mineralocorticoid receptor expression increases during embryonic stem cell-derived neuronal
8 differentiation through aldosterone-stimulated activation of its alternative promoters.

9

10 **Mathilde Munier[1,2], Geri Meduri[1,3], Say Viengchareun[1,2], Philippe Leclerc[4], Damien Le**
11 **Menuet[1,2,*], and Marc Lombès[1,2,5,*]**

12
13 *1- Inserm, U693, Le Kremlin-Bicêtre, F-94276, France;*
14 *2- Univ Paris-Sud 11, Faculté de Médecine Paris-Sud, UMR-S693, Le Kremlin-Bicêtre, F-94276,*
15 *France;*
16 *3- Service de Génétique Moléculaire, Pharmacogénétique, Hormonologie, Le Kremlin-Bicêtre*
17 *Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre F-94275, France;*
18 *4- IFR 93, Le Kremlin-Bicêtre, F-94275, France;*
19 *5- Service d'Endocrinologie et Maladies de la Reproduction, Assistance Publique-Hôpitaux de Paris,*
20 *Hôpital de Bicêtre, Le Kremlin-Bicêtre, F-94275, France.*

21
22 ***** These authors contributed equally to this work.

23
24 **Corresponding author :** Marc Lombès, Inserm U693, Faculté de Médecine Paris-Sud 11, 63, rue
25 Gabriel Péri, 94276 Le Kremlin-Bicêtre Cedex France. E-mail: marc.lombes@u-psud.fr

26
27 **Disclosure information:**
28 M. M., G.M, .S.V., P.L, D.L., M.L. have nothing to disclose.

29
30 **Key words:**
31 Mineralocorticoid receptor, embryonic stem cell, neuronal differentiation, aldosterone, promoters,
32 transcriptional regulation

33
34 **Grant supports:**
39

ABSTRACT

Mineralocorticoid receptor (MR) plays a critical role in brain function. However, the regulatory mechanisms controlling neuronal MR expression that constitutes a key element of the hormonal response are currently unknown. Two alternative P1 and P2 promoters drive human MR gene transcription. To examine promoter activities and their regulation during neuronal differentiation and in mature neurons, we generated stably transfected recombinant murine embryonic stem (ES) cell lines, namely P1-GFP and P2-GFP, in which each promoter drove the expression of the reporter gene Green Fluorescent Protein (GFP). An optimized protocol, using embryoid bodies and retinoic acid, permitted to obtain a reproducible neuronal differentiation as revealed by the decrease in phosphatase alkaline activity, the concomitant appearance of morphological changes (neurites) and the increase in the expression of neuronal markers (nestin, β-tubulin III, MAP2) as demonstrated by immunocytochemistry and qPCR. Using these cell-based models, we showed that MR expression increased by 5-fold during neuronal differentiation, MR being preferentially if not exclusively expressed in mature neurons. Although the P2 promoter was always weaker than the P1 promoter during neuronal differentiation, their activities increased by 7- and 5-fold, respectively and correlated with MR expression. Finally, while progesterone and dexamethasone were ineffective, aldosterone stimulated both P1 and P2 activity and MR expression, an effect that was abrogated by knockdown of MR by siRNA. Concluding, we provide evidence for a tight transcriptional control of MR expression during neuronal differentiation. Given the neuroprotective and antiapoptotic role proposed for MR, the neuronal differentiation of ES cell lines opens potential therapeutic perspectives in neurological and psychiatric diseases.

INTRODUCTION

The mineralocorticoid receptor (MR), a transcription factor belonging to the nuclear receptor superfamilly, is expressed both in epithelial tissues, where it plays a critical role in mediating aldosterone-regulated transepithelial sodium transport, and in non-epithelial tissues such as the cardiovascular system and central nervous system where it controls important cardiovascular functions and behavioral processes (1). MR binds both aldosterone and glucocorticoid hormones with a similar affinity. In the brain, although aldosterone-selective MR is expressed in hypothalamic sites involved in the regulation of salt appetite (2), the highest MR expression is found in the limbic structures particularly in hippocampal neurons, where it is physiologically occupied by glucocorticoids.

In the central nervous system, MR is involved in the regulation of the Hypothalamic-Pituitary-Adrenocortical (HPA) axis activity under basal and stress conditions (3). MR activity, at low glucocorticoid levels, is associated with cell excitability and long-term potentiation, a cellular model for learning and memory formation (4). Animal models of MR overexpression or inactivation have also brought important information on MR function in the brain. Indeed, mice specifically overexpressing MR in the forebrain exhibited a reduction of anxiety-like behavior (5, 6), while mice lacking limbic MR had a normal anxiety-like behavior but improved in learning processes (7, 8). Moreover, studies on hippocampal neurons recently proposed an anti-apoptotic role for MR (9, 10), confirming studies using a MR knockout mouse model, which showed degeneration of hippocampal granule cells in adulthood (11), while reduced neuronal death was observed in MR overexpressing transgenic mice after transient cerebral global ischemia (6).

A key step in the mineralocorticoid signaling is the MR expression level. Differential brain MR capacities correlating with distinct responses of the HPA axis in two rat strains initially pointed out to the importance of MR expression level as a determinant factor of its action (12). This was further exemplified by knockout or overexpressing MR animals models (5-8) . Even though MR expression levels constitute an essential element governing mineralocorticoid signaling in target tissues, very little is known concerning the regulatory mechanisms controlling neuronal MR abundance. It is well established that MR expression is regulated by transcriptional and post-transcriptional mechanisms (1). At the level of transcription, we have previously identified two functional promoters in the human

90   MR gene, referred to as P1 and P2, corresponding to the 5'-flanking regions of the two first

91   untranslated exons 1α and 1β (13). Functional characterization revealed that the P1 had a stronger

92   basal transcriptional activity than the P2 promoter. While both promoters were stimulated by

93   glucocorticoids, only P2 was activated by aldosterone. Moreover, as demonstrated in transgenic

94   animals, P1 promoter was active in all MR-expressing tissues including the brain, whereas P2

95   promoter activity was weaker and appeared to be restricted during development (14).

96   To define the molecular mechanisms governing MR expression during neuronal differentiation, we

97   have developed stably transfected recombinant murine embryonic stem (ES) cell lines, namely P1-

98   GFP and P2-GFP, in which each promoter drives the expression of the Green Fluorescent Protein

99   (GFP) used as a reporter gene. These models offer the possibility to investigate the regulation of MR

100 expression and of the promoter activities during the early stages of neuronal differentiation and in

101 mature neurons. We show that MR expression increases during neuronal differentiation which is

102 associated with a parallel aldosterone-regulated control of P1 and P2 promoter activities.

103

104 **MATERIALS AND METHODS**

105 *P1- and P2-GFP Constructs*

106   P1- and P2-GFP constructs were obtained from the pGL3-Enhancer Vector (Promega,

107 Charbonnieres, France), in which the luciferase gene was replaced by the GFP cDNA from pEGFP

108 plasmid (Ozyme, Saint Quentin en Yveline, France). The *HindIII-AvaII* fragment of the hMR gene,

109 referred to as P1, was amplified from the pGL2-HA plasmid (13) by PCR with GL1 and GL2 primers.

110 This amplicon was thereafter ligated into the *SmaI-HindIII* sites of pGL3-Enhancer-GFP vector. The

111 *SspI-SspI* fragment was extracted from the H31-P2 plasmid (15) by *EcoRI* and *EcoRV* digestion and

112 was inserted into the unique *SmaI* site of pGL3-Enhancer-GFP plasmid after filling in all recessive

113 ends with Klenow (Ozyme) treatment and dephosphorylation of pGL3-Enhancer by the Shrimp

114 Alcaline Phosphatase (Promega). Transgenes have been subsequently sequenced to verify their

115 integrity (*Service de Génétique Moléculaire, Pharmacogénétique, Hormonologie*, CHU Bicêtre,

116 France).

117   Other constructs using the same *HindIII-AvaII* fragment and the same *SspI-SspI* fragment of hMR

118   gene have been generated. They were obtained from H31-P1 and H31-P2 plasmids (15, 16), in which

119   we have inserted the entire coding sequence of the GFP.

120

121   ***Transfection Procedures***

122   For stable transfection, the 7241d embryonic stem (ES) cell line was used. This cell line has been

123   derived in Cooney's laboratory (Baylor College of Medicine, Houston Texas), from a blastocyst

124   obtained from the breeding of LRH +/- heterozygote mice (17) and was genotyped, phenotyped and

125   characterized as a standard wild type ES cell line (Le Menuet and Cooney, unpublished data). The

126   undifferentiated cells 7241d were seeded in 100 mm-Petri dishes one day before transfection. Five μg

127   of P1- or P2-GFP constructs were co-transfected with 1 μg of pcDNA3 plasmid, containing the

128   neomycin gene (Invitrogen, Cergy-Pontoise, France), using 15 μl Lipofectamine 2000 reagent

129   (Invitrogen). Forty-eight hours post-transfection, selection was initiated with 400 μg/ml of G418

130   (PAA, Les Mureaux, France). Neo-resistant clones were picked up after 5 days of G418 selection and

131   propagated using the same medium. Two transfections, for each construct, were carried out, resulting

132   in 11 neo-resistant clones having integrated the P1-GFP construct whereas 4 integrated the P2-GFP

133   construct. In addition, the constructs obtained from H31-P1 and H31-P2 plasmids were stably

134   transfected in undifferentiated ES cells.

135

136   ***Cell Culture***

137   Mouse ES cells were grown on 0.1% gelatin-coated plates (Sigma-Aldrich, Lyon, France) and on

138   feeder cells (STO Neomycin LIF, kindly provided by Dr Alan Bradley, The Wellcome Trust Sanger

139   Institute, UK) treated with 15 μg/ml mitomycin C (Sigma-Aldrich) for 4 hours. Cells were cultured at

140   37°C in a humidified incubator gassed with 5% CO_2.

141   ***Reagents*** - ES medium was composed of DMEM (PAA) containing 15% fetal calf serum (FCS

142   specifically tested for ES culture (AbCys SA, Paris, France), 1X non-essential amino acids (PAA), 2

143   mM glutamine (PAA), 100 U/ml penicillin (PAA), 100 μg/ml streptomycin (PAA), 20 mM Hepes

144   (PAA) and 100 μM β-mercaptoethanol (Sigma-Aldrich). Embryoid Bodies (EB) medium was similar

5

145   to ES medium except that it contained 10% FCS without β-mercaptoethanol. Neuron medium was

146   similar to EB medium but was supplemented with 5 μg/ml insulin (Sigma-Aldrich), 5 μg/ml

147   transferrin (Sigma-Aldrich), and 29 nM sodium selenate (Sigma-Aldrich).

148   ***Differentiation of ES cells into Neuronal-like cells*** - ES cells were cultured on feeder cells for two

149   days after thawing. Subsequently, they were cultured without feeder cells in ES medium with

150   Leukemia Inhibitory Factor (LIF) 1,000 U/ml (AbCys) and differentiation was started after 2 days. To

151   induce EB formation, ES cells were detached, dissociated into single cells with 0.25% trypsin

152   (Invitrogen) and then 1.10^6 ES cells were plated onto non-adherent bacterial Petri dishes (Greiner Bio-

153   one SAS, Courtaboeuf, France) in ES medium without LIF. EB medium with 1 μM all *trans*-retinoic

154   acid (Sigma-Aldrich) was added after 2 days and was changed every other day. At day 7, EB were

155   washed twice with PBS (PAA) and trypsinized for 10 min in a water bath at 37 °C. EB were then

156   gently but thoroughly resuspended in 10 ml EB medium, then centrifuged for 3 min at 400 g at room

157   temperature. The pellet was resuspended in neuron medium and the cell suspension was filtered

158   through a 40-μm nylon cell strainer (BD Biosciences, USA). The cell suspension was immediately

159   seeded at a density of 2.10^5 cells per cm^2. Neuron medium was changed every 2 days.

160   ***Cell Treatment*** - After 24 h incubation in Dextran-Charcoal Coated (DCC) medium, aldosterone

161   (Acros Organics, Halluin, France), dexamethasone or progesterone (Sigma-Aldrich), was added to the

162   culture medium at day 13 of the neuronal differentiation. At day 14, total RNA was extracted by the

163   Trizol reagent or cells were fixed.

164

165   ***Alkaline Phosphatase Assay***

166   Cells were fixed for 2 min in 4% PBS-buffered paraformaldehyde (Sigma-Aldrich) and were rinsed

167   once with PBS. During fixation, fresh staining solution was prepared by mixing Fast Red Violet,

168   Naphtol AS-BI phosphate and water (2:1:1), according to the Quantitative Alkaline Phosphatase ES

169   Characterization Kit protocol (Millipore, Saint Quentin en Yvelines, France). Fixed cells were

170   incubated for 15 min with the staining solution at room temperature in the dark. Cells were rinsed with

171   PBS and then photographed (microscope Motic AE21 and camera Olympus SP-51OUZ).

172

Immunocytochemistry

Cells were fixed with methanol for 10 min, rinsed with PBS-Tween 20 and incubated with 4% horse immunoglobulins for 20 min, prior to overnight incubation at 4°C, with the primary monoclonal antibodies diluted as follows: anti-tubulin beta III TU-20 (1/50) (AbCys), anti-nestin 4D4 (5 µg/ml) (AbCys), anti-APC CC1 (1/20) (Calbiochem, Nottingham, UK), and anti-GFAP G-A-5 (1/200) (Sigma-Aldrich). After endogenous peroxidase quenching with 3% H_2O_2 in PBS and washing, immunodetection was performed using the anti-mouse ImmPress reagent kit (Vector, Burlingame, CA) according to the manufacturer's instructions. Negative mouse ascites and pre-immune mouse immunoglobulins of the same sub-class were used as negative controls.

Confocal Immunofluorescence Microscopy

Cells were fixed with methanol for 10 min, rinsed with PBS-Tween 20 and incubated with PBS 5%-BSA 0.1% casein block for 20 min. Cells were then incubated overnight at 4°C, with anti-MR 39N polyclonal antibody (4 µg/ml) followed by incubation with Alexa Fluor 555 goat anti-rabbit (1/1000) (Molecular Probes) for 1 h at room temperature. The cells were next rinsed in PBS, and incubated with the monoclonal antibodies anti-tubulin beta III TU-20 (1/100) (AbCys), or anti-nestin 4D4 (5 µg/ml) (AbCys), or anti-GFAP G-A-5 (1/200) (Sigma-Aldrich), or anti-GFP (1/30) (AbCys) for 2 h at room temperature followed by washing and incubation with Alexa Fluor 488 goat anti-mouse (1/1000) (Molecular Probe) for 1 h at room temperature. After washing with PBS and mounting with Fluorescence Mounting Medium (Dako, Trappes, France), cells were analyzed and imaged by confocal fluorescence microscopy (Zeiss HAL confocal microscope). The anti-MR antibody (39N) was generated in rabbits immunized with the human MR 1-18 peptide and purified by affinity chromatography (Double X/XP boosting antibody production program, Eurogentec, Seraing, Belgium). The specificity of the anti-MR antibody was previously characterized (18,19).

DNA extraction

DNA was extracted from cells with lysis buffer composed of 50 mM Tris pH8, 10 mM EDTA, 10% SDS, 400 mM NaCl, and supplemented with proteinase K (Euromedex, Souffelweyrsheim,

201 France) 50 mg/ml, incubated overnight at 37°C, precipitated with isopropanol, rinsed with ethanol and

202 dissolved in water.

203

204 ***RT-PCR***

205   Total RNA was extracted with TRIZOL reagent (Invitrogen) according to the manufacturer's

206 recommendations and RNA were processed for RT-PCR analysis. Briefly, 2 μg of total RNA was

207 treated using the DNase I Amplification Grade procedure (Invitrogen). RNA was then reverse-

208 transcribed with 200 units of reverse transcriptase using the SuperscriptTM II kit (Invitrogen)

209 according to the manufacturer's recommendations using random hexamers (Promega). PCR were

210 performed with a thermocycler (Stratagene, Paris, France) in a final volume of 25 μl, in 1X PCR

211 buffer containing 1.5 mM $MgCl_2$, 10 pmol of sense and antisense primers (see supplemental table),

212 200 μM dNTP, 1 unit of *Taq* polymerase, and 2 μl of the reverse transcription reaction. The PCR

213 cycles were as followed: 95 °C for 5 min, specific hybridization temperature for 1 min, 72 °C for 1

214 min, during 1 cycle; 95 °C for 45 s, specific hybridization temperature for 45 s, 72 °C for 45 s, during

215 30 cycles; 72 °C for 7 min, during 1 cycle. Amplicons were thereafter separated onto agarose gels and

216 visualized under UV excitation.

217

218 ***Quantitative Real Time PCR***

219   Gene expression was quantified by real time PCR. Total RNA was processed for real time PCR

220 carried out on an ABI 7300 Sequence Detector (Applied Biosystems, Courtaboeuf, France). Briefly, 1

221 μg of total RNA was treated using the DNase I Amplification Grade procedure (Invitrogen). RNA was

222 then reverse-transcribed with 50 units of MultiScribe reverse transcriptase (Applied Biosystems).

223 Samples were diluted 10-fold, and then 1/20 of the reverse transcription reaction was used for PCR

224 using the Power SYBR® Green PCR master mix (Applied Biosystems). Final primer concentrations

225 were 300 nM for each primer (see supplemental table). Reaction parameters were 50 °C for 2 min

226 followed by 40 cycles at 95°C for 15 s, and 60 °C for 1 min. For preparation of standards, amplicons

227 were purified from agarose gel and subcloned into pGEMT-easy plasmid (Promega), then sequenced

228 to confirm the identity of each fragment. Standard curves were generated using serial dilutions of

229   linearized standard plasmids, spanning 6 orders of magnitude and yielding correlation coefficients

230   >0.98 and efficiencies of at least 0.95, in all experiments. Standard and sample values were

231   determined in duplicate from independent experiments. Relative expression within a given sample was

232   calculated as the ratio: attomol of specific gene/femtomol of 18S. Results are mean ± S.E.M and

233   represent the relative expression compared with that obtained with control cells, which was arbitrary

234   set at 1.

235

236   *MR knockdown by siRNA*

237   Neurons were transiently transfected at day 12 with 100 nM siRNA (Eurogentec; sequences were

238   reported in Supplemental Table), using Lipofectamine RNAiMAX (Invitrogen) in Opti-MEM

239   Reduced Serum Medium (Invitrogen) according to the manufacturer's recommendations. Six hours

240   post-transfection, cells were incubated in DCC medium for 24 h followed by an additional 24h

241   exposure to aldosterone. At day 14, total RNA was extracted and MR and GFP expression were

242   measured by qPCR.

243

244   *Statistical Analyses*

245   Results represent mean ± SEM with at least 6 samples for each condition. Statistical analyses were

246   performed using a non parametric Mann-Whitney test (Prism4, Graphpad Software, Inc., San Diego,

247   CA).

248

249   **RESULTS**

250   *Characterization of stably transfected embryonic stem cell lines P1-GFP and P2-GFP*

251   P1 and P2-GFP ES cell lines have been generated to examine the two hMR promoter activities

252   during neuronal differentiation. As shown in Figure 1A, the proximal P1 promoter contained the 5'-

253   flanking region (969 bp) of the exon 1α and part of this first untranslated exon (239 bp). The P2

254   promoter was composed of the 5'-flanking region (1682 bp) of the untranslated exon 1β and the first

255   123 bp of this exon. These promoter regions were inserted into the pGL3-Enhancer Vector, which

256   contains the SV40 enhancer, in order to enhance the basal activity of these promoters and thereby

257 facilitate detection of the reporter gene GFP. After stable transfection of murine ES cells, neomycin-

258 resistant clones were isolated and genomic integration of the constructs was determined by PCR

259 (Figure 1B). Several recombinant ES cell lines, namely P1-GFP and P2-GFP, were established. We

260 demonstrated the expression of GFP mRNA and endogenous MR mRNA by RT-PCR, in 7 days EB,

261 thus confirming the functionality of the constructs in these ES cell lines (Figure 1C). The GFP protein

262 was expressed in these EB, as visualized by fluorescence microscopy (Figure 1D). Similar results were

263 obtained using two other independent stably transfected cell lines P1 and P2-GFP, generated with

264 identical constructs except that they were devoid of enhancer, thereby validating our strategy (see

265 *Materials and Methods section*, data not shown). Altogether, these cell-based systems offer the

266 possibility to study MR promoter activities as well as the regulation of MR expression during the first

267 steps of neuronal differentiation and in mature neurons.

268

269 *Neuronal differentiation*

270   The neuronal differentiation protocol used in the present study, essentially followed one previously

271 described (20). Briefly, after withdrawal of LIF, ES-cells formed EB, which were incubated in non-

272 adhesive bacterial dishes with retinoic acid (RA) for 5 days. EB were dissociated and incubated in the

273 neuron specific medium, and after 3 days originated differentiated cells harbouring a neuron like

274 phenotype. While a strong alkaline phosphatase activity was detected in undifferentiated ES cells, this

275 activity dramatically decreased in RA-stimulated cells, thus confirming their commitment to neuronal

276 differentiation (Figure 2A). After 5 days treatment with RA, the expression of the neuronal progenitor

277 marker nestin and the mature neuronal marker Microtubule-Associated Protein-2 (MAP2) was already

278 detected by quantitative real time PCR in EB. Incubation with neuron specific medium readily

279 increased mRNA expression levels of these neuronal markers (Figure 2B-2C). The two other

280 independent stably transfected cell lines P1 and P2-GFP, the parental line and the D3 ES cell line

281 (ATTC number: CRL-11693), used as a wild type control, were differentiated into neurons according

282 to the same protocol. No appreciable differences in the expression profile of neuronal markers were

283 observed between the different cell lines. Therefore, the results represent the mean of all cell lines.

284 Immunocytochemical studies, performed at the end of the neuronal differentiation procedure, showed

285   that most cells expressed the neuronal markers nestin and βtubulin III (another marker of mature

286   neurons) and displayed elongated neuritic processes. Of note, few cells, clustered in some areas,

287   expressed the astrocyte marker GFAP (Glial Fibrillary Acidic Protein) or the oligodendrocyte marker

288   APC (Adenomatous Polyposis Coli) (Figure 2D). These results conclusively demonstrate that this

289   neuronal differentiation protocol allows to generate, in a reproducible manner, cultures mainly

290   composed of cells expressing immature and mature neuronal markers, but also comprising a minority

291   of cells expressing astroglial markers.

292

293   ***Regulation of MR expression during neuronal differentiation***

294   To investigate the molecular mechanisms regulating MR expression, we first examined endogenous

295   MR mRNA expression during neuronal differentiation by quantitative real-time PCR. We observed

296   that MR expression rose approximately by 3-fold in EB and by 5-fold in mature neurons (Figure 3).

297   As described above, a similar MR expression pattern was observed in all ES cell lines. Thus, we were

298   able to define the temporal expression pattern of MR during ES differentiation and to demonstrate a

299   progressive increase of MR abundance along with neuronal commitment. Double immunolabeling

300   experiments using anti-MR (A) associated with anti-nestin (B) antibodies have been performed

301   (Figure 4). The merged panel (C) shows the absence of MR and nestin colocalization, indicating that

302   nestin-positive cells did not express the MR at a detectable level. On the contrary, double

303   immunolabelling with anti-βtubulin III revealed a specific MR and βtubulin III colocalization (D-E-F).

304   GFAP-positive cells did not express the MR (G-H-I), similarly to the nestin-positive cells. For each

305   experiment, the negative control was performed using pre-immune mouse immunoglobulins of the

306   same sub-class or non reactive mouse ascites (data not shown). Of note, MR localization is nucleo-

307   cytoplasmic under these experimental conditions. Altogether, these data suggest that MR is

308   preferentially if not exclusively expressed in mature neurons.

309   We next examined the variation of P1 and P2 promoter activities during neuronal differentiation of

310   P1 and P2-GFP ES cell lines. The relative GFP expression was measured by quantitative real-time

311   PCR, and was considered as a direct index of promoter activity. Figure 5A shows a 7-fold increase in

312   GFP transcripts in P1-GFP derived differentiated neurons compared to that measured in the

313 corresponding EB stage. Similarly, a 5-fold increase in GFP mRNA levels was observed in P2-GFP

314 derived neurons, indicating that both P1 and P2 promoters were activated during neuronal

315 differentiation. We also compared the relative GFP expression driven by either P1 or P2 promoter in

316 undifferentiated ES cells as well as in neurons (Figure 5B). We thus demonstrated that the P1 activity

317 was always higher than P2 activity by a 46-fold and a 6-fold factor in undifferentiated ES cells and in

318 mature neurons, respectively. These findings were reproducibly obtained with the other recombinant

319 ES cell lines. These results confirmed previous data obtained by transient transfection assays

320 performed in fibroblast-like cells and in transgenic mice (13, 14) which indicated that the P1 promoter

321 basal transcriptional activity is also stronger than that of P2 promoter, irrespective of the model

322 studied. Double staining showed that GFP was present in P1-GFP MR-positive cells (Figure 5C),

323 indicating that P1 promoter was transcriptionally active in neurons. In P2-GFP cells, GFP expression

324 was most of the times below the immunodetection threshold, confirming that P2 activity is weaker

325 than P1 activity. Altogether, our results clearly demonstrate that P1 and P2 promoters are both

326 effective in driving MR expression throughout neuronal differentiation but with different strengths.

327

328 ***Hormonal regulation of P1 and P2 activity and MR expression in ES cell-derived neurons***.

329   Previously, *in vitro* characterization of the P1 and P2 promoters revealed that both promoters were

330 activated by dexamethasone, *via* the glucocorticoid receptor (GR), whereas only P2 was activated by

331 aldosterone, *via* MR (13). Moreover, it has been also demonstrated that progesterone, *via* the

332 progesterone receptor (PR), increases MR mRNA levels in primary hippocampal neuron cultures (21).

333 We thus decided to investigate the impact of these steroid hormones on MR expression in ES cell-

334 derived neurons. First, we examined the expression pattern of GR and PR and demonstrated that their

335 transcript levels also increased by 7-fold and 20-fold, respectively during neuronal differentiation

336 (*Supplemental figure*). These results provide evidence that GR and PR are progressively and more

337 intensively expressed during the first steps of neuronal differentiation, thus suggesting that they could

338 represent key players in ES cell-derived mature neuron function.

339   We next exposed ES cell-derived neurons to aldosterone, dexamethasone or progesterone at day 13

340 of differentiation. Steroid-induced modification of P1 and P2 activity and MR mRNA expression were

341   determined after 24 h treatment using quantitative real-time PCR. As shown in Figure 6A, 100 nM

342   aldosterone increased GFP mRNA expression in P1-GFP neurons by 1.4-fold, whereas dexamethasone

343   and progesterone failed to exert any significant effect. Dose-dependent curves demonstrated that the

344   P1 promoter was activated only at the highest aldosterone concentration (Figure 6B). On the other

345   hand, the P2 promoter was highly sensitive to aldosterone action since GFP mRNA levels already

346   increased by a 1.5-fold factor in P2-GFP neurons at 1 nM aldosterone concentration (Figure 6C and

347   6D). Similarly, neuronal MR expression was significantly enhanced in the presence of 100 nM

348   aldosterone, following the evolution of aldosterone-induced P1 promoter activity (Figure 6E and 6F).

349   In sharp contrast, dexamethasone and progesterone had no significant effect on GFP and MR mRNA

350   levels in these ES cell-derived neurons, suggesting that these steroid hormones did not regulate MR

351   expression in neurons. In order to examine the involvement of MR in the regulation of its own

352   promoters' activity, we decided to knockdown MR expression by a siRNA strategy with two unrelated

353   MR-specific siRNA in the P2-GFP ES-derived neurons since they exhibited the highest sensitivity to

354   aldosterone action. As shown in Figure 7, compared with scrambled siRNA, a decrease in MR mRNA

355   expression was obtained by each of two MR siRNA (Figure 7A) and was accompanied by the

356   disappearance of aldosterone-stimulated GFP expression (Figure 7B). Altogether, these findings

357   provide support for the involvement of MR, but not of GR, in the activation of both P1 and P2

358   promoters, pointing to the implication of the mineralocorticoid signaling pathway in the regulatory

359   mechanisms governing MR expression in mature neurons.

360

361   **DISCUSSION**

362   In the present study, we have established a novel ES cell model of neuronal differentiation to assess

363   the molecular mechanisms involved in MR expression using stably transfected P1-GFP and P2-GFP

364   ES cell lines. We found that MR expression gradually increases during neuronal differentiation and

365   demonstrated that MR is preferentially, if not exclusively, expressed in mature neurons. This is

366   concomitant with the increase of GR and PR expression, underlying the potential importance of these

367   steroid receptors during neurogenesis and differentiation. We showed that both P1 and P2 promoter

368   drive neuronal MR expression, the former being always stronger than the latter. Finally, we provided

369 evidence that aldosterone treatment significantly induces both MR expression and P1 and P2 activity

370 in mature neurons. These findings suggest the involvement of MR activation in the stimulation of P1

371 and P2 activities and on MR expression in mature neurons, a hypothesis supported by MR knockdown

372 experiments. However, the precise molecular mechanisms responsible for the aldosterone-induced MR

373 expression, and how P1 and P2 promoters are specifically activated by aldosterone remain to be

374 determined.

375   The present work constitutes a detailed study characterizing MR expression during neuronal ES

376 cell differentiation. Indeed, the ES cell model has been shown to be quite relevant in the neuronal field

377 and widely used to decipher the activity or function of genes of interest and to better understand the

378 pathophysiological mechanisms involved in some neurodegenerative diseases (22). A previous initial

379 report demonstrated an increase of MR mRNA expression associated with a decrease of GR and PR

380 expression during the first six days of spontaneous differentiation of human and murine ES cells (23).

381 We provide evidence that the level of steroid receptors including MR, GR and PR increases during

382 neuron commitment of murine ES cells in accordance with the increase of PR content demonstrated

383 during differentiation of dopamine neurons derived from mouse ES cells (24).

384   It is well established that MR is expressed in the limbic system most notably in the hippocampus

385 (25). Within the hippocampus, the highest density occurs in pyramidal cells of the CA1 region and in

386 granule neurons of the dentate gyrus but in the adult hippocampus MR is not expressed in the neuronal

387 stem cells (26). As opposed to GR, MR seems to be specifically expressed in mature neurons and is

388 absent in glial cells (26), consistent with our findings which reveal that the majority of ES-derived

389 mature neurons are MR-positive. In contrast, MR does not colocalize with GFAP-positive cells even

390 though an increase of MR-expressing astrocytes was been reported in the striatum after ischemic

391 conditions (27).

392   The question on the precise subcellular localization of neuronal MR is still debated, owing to the

393 dual possibility of the classical nuclear tropism of MR acting as a hormone-dependent transcription

394 factor (28, 29) and of the putative membrane MR mediating rapid, nongenomic effects *via* pre- as well

395 as postsynaptic pathways (30). To further investigate this subcellular trafficking, we used ES-

396 differentiated mature neurons which were submitted to aldosterone or glucocorticoid exposure. Under

14

397 basal conditions, MR mostly resided in the cytoplasm of neurons with no obvious nuclear

398 translocation after aldosterone treatment, supporting the possibility of a membrane-bound MR. In

399 contrast, dexamethasone or corticosterone induced a clear nucleocytoplasmic redistribution (data not

400 shown). Given the coexpression with neuronal GR, we formulate the hypothesis that GR plays an

401 indispensable role in MR nuclear trafficking, via GR-MR heterocomplexes, in agreement with a recent

402 study demonstrating the importance of the presence of GR in mediating MR-dependant transcription

403 (31).

404 Another important issue, given the potential neuroprotective effect of MR (32, 33) is a better

405 understanding of the regulatory mechanisms that control neuronal MR expression. Beside

406 transcriptional control, the promoter activity during neuronal differentiation could also be regulated by

407 epigenetic mechanisms. Indeed, some transcription factors (Oct4, Nanog, and Sox2) or histone

408 modification and DNA methylation are coordinated to control the expression of pluripotent versus

409 developmental genes in ES cells and during *in vitro* differentiation. A recent study shows that the

410 promoters of a third of the genes expressed in undifferentiated ES cells are methylated and that these

411 genes are implicated in development (34). Along this line, *in silico* analysis of the P2 promoter

412 sequence revealed the presence of several GC-rich regions likely to be methylated, which could

413 account for its weak activity. In a recent study, pyrosequencing of two CpG islands within rat MR

414 gene promoter demonstrated a correlation between methylation and MR expression (35). Weaver et al

415 showed that the methylation of CpG on the transcription factor NGFI-A (Nerve Growth Factor-

416 Inductible protein A) response elements located in the GR promoter resulted in a transcriptional

417 repression in hippocampal neurons (36). Interestingly, P2 promoter exhibited two NGFI-A response

418 elements at position −834 bp and −857 bp, which could explain the modulation of this promoter

419 activity observed during ES cells neuronal differentiation. Recently, a novel role for the β promoter of

420 rat MR gene was defined (37). This promoter has a weak activity under basal conditions, but its

421 activity increases under hypothermic anoxia in neonatal rat hippocampus. Given that the rat β

422 promoter is the homologous of the human P2 promoter gene, this finding suggests a potential role for

423 this otherwise weak promoter and opens interesting pathophysiological perspectives.

424   It has been proposed that neuronal MR expression is subjected to a tight regulatory control by

425 different stimuli. For instance, MR expression increases in primary hippocampus neuron cultures after

426 serotonin exposure (38) or after antidepressant treatment in adrenalectomized male mice (39).

427 Dexamethasone and progesterone also increase rat MR gene transcription in primary hippocampal

428 neurons (21, 40). Using ES-derived mature neurons, we demonstrated that aldosterone but not

429 glucocorticoid or progesterone significantly increases both neuronal MR expression as well as P1 and

430 P2 activity. Moreover, we showed that down-regulation of MR expression by siRNA in ES-derived

431 neurons leads to a disappearance of aldosterone-stimulated GFP expression, providing evidence that

432 MR is at least in part implicated in the regulation of its own promoter activity. This does not exclude

433 that other mechanisms as recently proposed (41) might be involved in the aldosterone-regulated P1

434 and P2 promoter activities. However, the mechanisms by which aldosterone-activated MR controls

435 MR promoter activity and whether this occurs through direct or indirect interaction with others

436 transcription factors remain to be established. Collectively, these findings suggest a pivotal role of

437 neuronal MR abundance and of its subcellular localization which are likely important players involved

438 in the complex developmental regulatory pattern (42, 43), the corticosteroid-regulated synaptic

439 plasticity (30) and neuronal excitability (4). The importance of MR function in the brain is largely

440 demonstrated by animal models of MR overexpression or inactivation. No major morphological

441 alteration of the CNS was detected in adult MR-/- mice, suggesting that MR is mainly involved in the

442 maintenance of cellular and structural integrity of neurons rather that in CNS development itself. This

443 is in accordance with the neuroprotective and antiapoptotic role proposed for MR (10, 32). Taken

444 together, these experimental data emphasize the physiological and pathophysiological importance of

445 MR in the limbic brain. In this context, neuronal differentiation of ES cell lines proves to be a useful

446 model to investigate novel signaling pathways involved in modulation of neuronal MR expression,

447 opening some potential therapeutic perspectives in neurological and psychiatric diseases.

448

449

450

451

REFERENCES

1. Viengchareun S, Le Menuet D, Martinerie L, Munier M, Pascual-Le Tallec L, Lombes M 2007 The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal 5:e012

2. Geerling JC, Loewy AD 2006 Aldosterone-sensitive neurons in the nucleus of the solitary: efferent projections. J Comp Neurol 498:223-250

3. De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M 1998 Brain corticosteroid receptor balance in health and disease. Endocr Rev 19:269-301

4. Joels M 2008 Functional actions of corticosteroids in the hippocampus. Eur J Pharmacol 583:312-321

5. Rozeboom AM, Akil H, Seasholtz AF 2007 Mineralocorticoid receptor overexpression in forebrain decreases anxiety-like behavior and alters the stress response in mice. Proc Natl Acad Sci U S A 104:4688-4693

6. Lai M, Horsburgh K, Bae SE, Carter RN, Stenvers DJ, Fowler JH, Yau JL, Gomez-Sanchez CE, Holmes MC, Kenyon CJ, Seckl JR, Macleod MR 2007 Forebrain mineralocorticoid receptor overexpression enhances memory, reduces anxiety and attenuates neuronal loss in cerebral ischaemia. Eur J Neurosci 25:1832-1842

7. Berger S, Wolfer DP, Selbach O, Alter H, Erdmann G, Reichardt HM, Chepkova AN, Welzl H, Haas HL, Lipp HP, Schutz G 2006 Loss of the limbic mineralocorticoid receptor impairs behavioral plasticity. Proc Natl Acad Sci U S A 103:195-200

8. Brinks V, Berger S, Gass P, de Kloet ER, Oitzl MS 2009 Mineralocorticoid receptors in control of emotional arousal and fear memory. Horm Behav

9. Almeida OF, Conde GL, Crochemore C, Demeneix BA, Fischer D, Hassan AH, Meyer M, Holsboer F, Michaelidis TM 2000 Subtle shifts in the ratio between pro- and antiapoptotic molecules after activation of corticosteroid receptors decide neuronal fate. FASEB J 14:779-790

10. Crochemore C, Lu J, Wu Y, Liposits Z, Sousa N, Holsboer F, Almeida OF 2005 Direct targeting of hippocampal neurons for apoptosis by glucocorticoids is reversible by mineralocorticoid receptor activation. Mol Psychiatry 10:790-798

11. Gass P, Kretz O, Wolfer DP, Berger S, Tronche F, Reichardt HM, Kellendonk C, Lipp HP, Schmid W, Schutz G 2000 Genetic disruption of mineralocorticoid receptor leads to impaired neurogenesis and granule cell degeneration in the hippocampus of adult mice. EMBO Rep 1:447-451

12. Oitzl MS, van Haarst AD, Sutanto W, de Kloet ER 1995 Corticosterone, brain mineralocorticoid receptors (MRs) and the activity of the hypothalamic-pituitary-adrenal

493   (HPA) axis: the Lewis rat as an example of increased central MR capacity and a
494   hyporesponsive HPA axis. Psychoneuroendocrinology 20:655-675

495 13. Zennaro MC, Le Menuet D, Lombes M 1996 Characterization of the human mineralocorticoid
496   receptor gene 5'-regulatory region: evidence for differential hormonal regulation of two
497   alternative promoters via nonclassical mechanisms. Mol Endocrinol 10:1549-1560

498 14. Le Menuet D, Viengchareun S, Penfornis P, Walker F, Zennaro MC, Lombes M 2000
499   Targeted oncogenesis reveals a distinct tissue-specific utilization of alternative promoters of
500   the human mineralocorticoid receptor gene in transgenic mice. J Biol Chem 275:7878-7886

501 15. Le Menuet D, Isnard R, Bichara M, Viengchareun S, Muffat-Joly M, Walker F, Zennaro MC,
502   Lombes M 2001 Alteration of cardiac and renal functions in transgenic mice overexpressing
503   human mineralocorticoid receptor. J Biol Chem 276:38911-38920

504 16. Le Menuet D, Zennaro MC, Viengchareun S, Lombes M 2000 Transgenic mouse models to
505   study human mineralocorticoid receptor function in vivo. Kidney Int 57:1299-1306

506 17. Gu P, Goodwin B, Chung AC, Xu X, Wheeler DA, Price RR, Galardi C, Peng L, Latour AM,
507   Koller BH, Gossen J, Kliewer SA, Cooney AJ 2005 Orphan nuclear receptor LRH-1 is
508   required to maintain Oct4 expression at the epiblast stage of embryonic development. Mol
509   Cell Biol 25:3492-3505

510 18. Martinerie L, Viengchareun S, Delezoide AL, Jaubert F, Sinico M, Prevot S, Boileau P,
511   Meduri G, Lombes M 2009 Low renal mineralocorticoid receptor expression at birth
512   contributes to partial aldosterone resistance in neonates. Endocrinology 150:4414-4424

513 19. Viengchareun S, Kamenicky P, Teixeira M, Butlen D, Meduri G, Blanchard-Gutton N,
514   Kurschat C, Lanel A, Martinerie L, Sztal-Mazer S, Blot-Chabaud M, Ferrary E, Cherradi N,
515   Lombes M 2009 Osmotic stress regulates mineralocorticoid receptor expression in a novel
516   aldosterone-sensitive cortical collecting duct cell line. Mol Endocrinol 23:1948-1962

517 20. Bibel M, Richter J, Lacroix E, Barde YA 2007 Generation of a defined and uniform
518   population of CNS progenitors and neurons from mouse embryonic stem cells. Nat Protoc
519   2:1034-1043

520 21. Castren M, Patchev VK, Almeida OF, Holsboer F, Trapp T, Castren E 1995 Regulation of rat
521   mineralocorticoid receptor expression in neurons by progesterone. Endocrinology 136:3800-
522   3806

523 22. Crews L, Mizuno H, Desplats P, Rockenstein E, Adame A, Patrick C, Winner B, Winkler J,
524   Masliah E 2008 Alpha-synuclein alters Notch-1 expression and neurogenesis in mouse
525   embryonic stem cells and in the hippocampus of transgenic mice. J Neurosci 28:4250-4260

526 23. Xie CQ, Jeong Y, Fu M, Bookout AL, Garcia-Barrio MT, Sun T, Kim BH, Xie Y, Root S,
527   Zhang J, Xu RH, Chen YE, Mangelsdorf DJ 2009 Expression profiling of nuclear receptors in
528   human and mouse embryonic stem cells. Mol Endocrinol 23:724-733

529 24. Diaz NF, Guerra-Arraiza C, Diaz-Martinez NE, Salazar P, Molina-Hernandez A, Camacho-
530   Arroyo I, Velasco I 2007 Changes in the content of estrogen alpha and progesterone receptors
531   during differentiation of mouse embryonic stem cells to dopamine neurons. Brain Res Bull
532   73:75-80

533 25. Reul JM, de Kloet ER 1985 Two receptor systems for corticosterone in rat brain:
534   microdistribution and differential occupation. Endocrinology 117:2505-2511

535 26. Garcia A, Steiner B, Kronenberg G, Bick-Sander A, Kempermann G 2004 Age-dependent
536   expression of glucocorticoid- and mineralocorticoid receptors on neural precursor cell
537   populations in the adult murine hippocampus. Aging Cell 3:363-371

538 27. Oyamada N, Sone M, Miyashita K, Park K, Taura D, Inuzuka M, Sonoyama T, Tsujimoto H,
539   Fukunaga Y, Tamura N, Itoh H, Nakao K 2008 The role of mineralocorticoid receptor
540   expression in brain remodeling after cerebral ischemia. Endocrinology 149:3764-3777

541 28. Nishi M, Ogawa H, Ito T, Matsuda KI, Kawata M 2001 Dynamic changes in subcellular
542   localization of mineralocorticoid receptor in living cells: in comparison with glucocorticoid
543   receptor using dual-color labeling with green fluorescent protein spectral variants. Mol
544   Endocrinol 15:1077-1092

545 29. Nishi M, Kawata M 2007 Dynamics of glucocorticoid receptor and mineralocorticoid
546   receptor: implications from live cell imaging studies. Neuroendocrinology 85:186-192

547 30. Olijslagers JE, de Kloet ER, Elgersma Y, van Woerden GM, Joels M, Karst H 2008 Rapid
548   changes in hippocampal CA1 pyramidal cell function via pre- as well as postsynaptic
549   membrane mineralocorticoid receptors. Eur J Neurosci 27:2542-2550

550 31. Tsugita M, Iwasaki Y, Nishiyama M, Taguchi T, Shinahara M, Taniguchi Y, Kambayashi M,
551   Nishiyama A, Gomez-Sanchez CE, Terada Y, Hashimoto K 2009 Glucocorticoid receptor
552   plays an indispensable role in mineralocorticoid receptor-dependent transcription in GR-
553   deficient BE(2)C and T84 cells in vitro. Mol Cell Endocrinol 302:18-25

554 32. Fujioka A, Fujioka T, Ishida Y, Maekawa T, Nakamura S 2006 Differential effects of prenatal
555   stress on the morphological maturation of hippocampal neurons. Neuroscience 141:907-915

556 33. Macleod MR, Johansson IM, Soderstrom I, Lai M, Gido G, Wieloch T, Seckl JR, Olsson T
557   2003 Mineralocorticoid receptor expression and increased survival following neuronal injury.
558   Eur J Neurosci 17:1549-1555

559 34. Fouse SD, Shen Y, Pellegrini M, Cole S, Meissner A, Van Neste L, Jaenisch R, Fan G 2008
560   Promoter CpG methylation contributes to ES cell gene regulation in parallel with Oct4/Nanog,
561   PcG complex, and histone H3 K4/K27 trimethylation. Cell Stem Cell 2:160-169

562 35. Martinez-Arguelles DB, Culty M, Zirkin BR, Papadopoulos V 2009 In utero exposure to di-
563   (2-ethylhexyl) phthalate decreases mineralocorticoid receptor expression in the adult testis.
564   Endocrinology 150:5575-5585

565   36.   Weaver IC, D'Alessio AC, Brown SE, Hellstrom IC, Dymov S, Sharma S, Szyf M, Meaney
566   MJ 2007 The transcription factor nerve growth factor-inducible protein a mediates epigenetic
567   programming: altering epigenetic marks by immediate-early genes. J Neurosci 27:1756-1768
568   37.   Kang P, Rogalska J, Walker CA, Burke M, Seckl JR, Macleod MR, Lai M 2009 Injury-
569   induced mineralocorticoid receptor expression involves differential promoter usage: a novel
570   role for the rat MRbeta variant. Mol Cell Endocrinol 305:56-62
571   38.   Lai M, McCormick JA, Chapman KE, Kelly PA, Seckl JR, Yau JL 2003 Differential
572   regulation of corticosteroid receptors by monoamine neurotransmitters and antidepressant
573   drugs in primary hippocampal culture. Neuroscience 118:975-984
574   39.   Heydendael W, Jacobson L 2008 Differential effects of imipramine and phenelzine on
575   corticosteroid receptor gene expression in mouse brain: potential relevance to antidepressant
576   response. Brain Res 1238:93-107
577   40.   Castren M, Trapp T, Berninger B, Castren E, Holsboer F 1995 Transcriptional induction of rat
578   mineralocorticoid receptor gene in neurones by corticosteroids. J Mol Endocrinol 14:285-293
579   41.   Bunda S, Wang Y, Mitts TF, Liu P, Arab S, Arabkhari M, Hinek A 2009 Aldosterone
580   stimulates elastogenesis in cardiac fibroblasts via mineralocorticoid receptor-independent
581   action involving the consecutive activation of Galpha13, c-Src, the insulin-like growth factor-I
582   receptor, and phosphatidylinositol 3-kinase/Akt. J Biol Chem 284:16633-16647
583   42.   Kretz O, Schmid W, Berger S, Gass P 2001 The mineralocorticoid receptor expression in the
584   mouse CNS is conserved during development. Neuroreport 12:1133-1137
585   43.   Vazquez DM, Lopez JF, Morano MI, Kwak SP, Watson SJ, Akil H 1998 Alpha, beta, and
586   gamma mineralocorticoid receptor messenger ribonucleic acid splice variants: differential
587   expression and rapid regulation in the developing hippocampus. Endocrinology 139:3165-
588   3177

FIGURE LEGENDS

Figure 1: Generation of hMR promoter-GFP expressing stable ES cell lines

A) Schematic representation of the two P1-GFP and P2-GFP constructs. The 5'-flanking regions of hMR gene contains the two first untranslated exons 1α and 1β (*solid boxes*). The *Hind III-Ava II* (-969, +239) P1 fragment and *SspI-SspI* (-1682, +123) P2 fragment were used to generate P1-GFP and P2-GFP plasmids, respectively. The GFP (*hatched box*) was used as a reporter gene. As described in the "Materials and Methods" section the pGL3-Enhancer Vector contains the SV40 Enhancer (*black box*). **B**) PCR genotyping of undifferentiated resistant cell lines (numbered 1 to 7). Rapsn was used as internal genomic control. **C**) RT-PCR analyses of GFP, MR, β-actin (used as internal control) mRNA

600   expression in 7 day embryoid bodies (from 1.10^6 cells in suspension in 15% FCS supplemented

601   medium). **D**) GFP protein expression was observed in 7 day embryoid bodies (from 1.10^6 cells in

602   suspension in 15% FCS supplemented medium). Original magnification: x20

603

604   **Figure 2: Neuronal differentiation of ES cell lines**

605   **A**) Alkaline Phosphatase activity of ES cells and neurons. Alkaline phosphatase activity was measured

606   using the colorimetric Alkaline Phosphatase Detection assay kit. Original magnification: x10 **B, C**)

607   Relative Nestin and MAP2 mRNA expression levels were determined using qPCR at different stages

608   of differentiation: undifferentiated ES cells, embryoid bodies (EB) and neurons. Results are means ±

609   SEM of six independent experiments of three samples performed in duplicate for each developmental

610   stage, and represent the relative expression compared with basal levels of ES (arbitrarily set at 1). ***

611     $P<0.001$. Mann Whitney test. Relative mRNA expression is normalized to 18S rRNA expression (see

612   Materials and Methods section). **D**) Immunocytochemical detection of Nestin, β-tubulin III, GFAP and

613   APC in neurons. Original magnification: x40.

614

615   **Figure 3: MR expression during neuronal differentiation**

616   Relative MR mRNA expression levels were determined using qPCR at different stages of

617   differentiation: undifferentiated ES cells, embryoid bodies (EB) and neurons. Results are means ±

618   SEM of six independent experiments of three samples performed in duplicate for each developmental

619   stage and represent the relative expression compared with basal levels of ES (arbitrarily set at 1). ***

620     $P<0.001$. Mann Whitney test. Relative mRNA expression is normalized to 18S rRNA expression (see

621   Materials and Methods section).

622

623   **Figure 4: MR is exclusively expressed in neurons**

624   Double immunolabelling analyses of neurons with antibodies against MR (red) (*left panel*), Nestin

625   (green), β-tubulin III (green), and GFAP (green) (*middle panel*), and merge (*right panel*) . Original

626   magnification: x40.

627

Figure 5: Comparison of P1 and P2 activity during neuronal differentiation

A) Relative GFP mRNA expression levels, which represent P1 and P2 activity, were determined using qPCR at different stages of differentiation: embryoid bodies (EB) and neurons. Results are means ± SEM of at least four independent experiments of three samples performed in duplicate and represent the relative expression compared with basal levels in embryoid bodies (arbitrarily set at 1). ** $P<0.01$. Mann Whitney test. Relative mRNA expression is normalized to 18S rRNA expression (see Materials and Methods section). **B**) Relative GFP mRNA expression levels were determined using qPCR at different stages of differentiation: ES cells and neurons. Results are means ± SEM of at least four independent experiments of three samples performed in duplicate and represent the relative P2 activity compared with basal levels of P1 activity (arbitrarily set at 1). ** $P<0.01$. Mann Whitney test. Relative mRNA expression is normalized to 18S rRNA expression (see Materials and Methods section). **C**) Double immunolabelling analyses of neurons with antibodies against MR (red) (*left panel*), and GFP (green) (*middle panel*), and merge (*right panel*). Original magnification: x40.

Figure 6: Hormonal regulation of P1 and P2 activity and MR expression.

Neurons were exposed to 100 nM aldosterone (ALDO), dexamethasone (DXM) or progesterone (PROG) (**A,C,E**) or to increasing concentrations of aldosterone (1 to 100 nM) (**B,D,F**).

A, B, C, D) Relative GFP mRNA expression levels were determined using qPCR. Results are means ± SEM of four independent experiments of six samples performed in duplicate and represent the relative expression compared with basal levels of control untreated cells (C) (arbitrarily set at 1). *** $P<0.001$ ** $P<0.01$ * $P<0.05$. Mann Whitney test. Relative mRNA expression is normalized to 18S rRNA expression (see Materials and Methods section). **E, F**) Relative MR mRNA expression levels were determined using qPCR. Results are means ± SEM of four independent experiments of six samples performed in duplicate and represent the relative expression compared with basal levels of control untreated cells (C) (arbitrarily set at 1). *** $P<0.001$. Mann Whitney test. Relative mRNA expression is normalized to 18S rRNA expression (see Materials and Methods section).

656 **Figure 7: MR down-regulation inhibits aldosterone-induced P2 promoter activity.**

657 Neurons were transfected with either the control scrambled siRNA (scr MR) or by two unrelated MR

658 siRNA (si1 MR, si2 MR). After transfection, neurons were incubated or not with 100 nM aldosterone

659 (ALDO).

660 **A)** Relative MR mRNA expression levels were determined using qPCR. Results are means ± SEM of

661 six samples performed in duplicate and represent the relative expression compared with basal levels of

662 control scrambled siRNA transfected (scr MR) (arbitrarily set at 1). ** $P<0.01$. Mann Whitney test.

663 Relative mRNA expression is normalized to 18S rRNA expression (see Materials and Methods

664 section).

665 **B)** Relative GFP mRNA expression levels were determined using qPCR. Results are means ± SEM of

666 six samples performed in duplicate and represent the relative expression compared with basal levels of

667 control untreated cells (C) (arbitrarily set at 1). *** $P<0.001$ ** $P<0.01$. Mann Whitney test. Relative

668 mRNA expression is normalized to 18S rRNA expression (see Materials and Methods section).

669